Clinical Trials
Treatment of retinal diseases is a rapidly changing field of medicine with new techniques and procedures being developed every year. Southwest Retina Specialists has been involved with research over the last six years for a variety of retina conditions, including Diabetic Macular Edema, Vitreous Hemorrhage with surgical intervention, and Age-Related Macular Degeneration.
While clinical trials are always voluntary, to qualify, patients need to go through a screening process prior to enrollment. Each studies eligibility and criteria vary.
Please contact one of our study coordinators, Kasey Dalrymple or Rae Barbee at 806-351-1870 (ext. 1113 or ext. 1148) if you are interested in being screened or want more information on a clinical trial being conducted.
You can learn more about each trial and how to participate in a clinical trial at:
http://www.ClinicalTrials.gov
http://www.fda.gov
We have completed multiple studies with a variety of sponsors, including several notable projects. Among them are the ISEE2008 and ISEE2009 studies for the drug Izervey by Astellas Pharmaceuticals, in which we enrolled a study-high of 15 patients. These studies helped pave the way for FDA approval of Izervey for the treatment of geographic atrophy caused by Dry AMD. Other significant studies include the GLOW and DAYLIGHT trials by Kodiak Sciences, which contributed to the advancement of ongoing research in this field.
Current Studies
Sponsor: Annexon
Study: ANX007-DA-02
Study Rational: A Phase 3 Study to access the drug ANX007 for the treatment of Dry AMD
Sponsor: EyeBio Tech
Study: EYE-RES-102
Study Rational: A Phase 2/3 Study to access the drug EYE103 for the treatment of Diabetic Macular Edema
Sponsor: EyeBio Tech
Study: EYE-TIE-201
Study Rational: A Phase 1/2 Study to access the drug EYE201 for the treatment of Wet AMD or Diabetic Macular Edema
Sponsor: EyeBio Tech
Study: EYE-RES-103
Study Rational: A Phase 2/3 Study to access the drug EYE103 for the treatment of Diabetic Macular Edema
Sponsor: EyePoint Pharmaceuticals
Study: EYP-1901-302
Study Rational: A Phase 3 Study to access the drug EYP-1901 for the treatment of Wet AMD
Sponsor: Genentech
Study: ML43000
Study Rational: A Phase 4 Study to assess corneal endothelial cells in patients with Wet AMD treated with the Port Delivery System with Ranibizumab
Sponsor: Kodiak Sciences
Study: KS301P108 GLOW2
Study Rational: A Phase 3 Study to access the drug KSI-301 for the treatment of Diabetic Retinopathy
Sponsor: Kodiak Sciences
Study: KS301P109 DAYBREAK
Study Rational: A Phase 3 Study to access the drug KSI-301 and KSI-501 for the treatment of Wet AMD
Upcoming Studies
Sponsor: 4DMT
Study: 4FRONT2
Study Rational: A Phase 3 Study to access the drug 4D-150 for the treatment of Wet AMD
Sponsor: EyeBio Tech
Study: EYE-RES-104
Study Rational: A Phase 2 Study to access the drug EYE103 for the treatment of Wet AMD or Macular Edema following branch retinal vein occlusion